As we start off 2026, I wanted to quickly look back at the research that I published in peer-reviewed journals last year. Here’s the list:
Shafrin J, Jadhav K, Warren C, Quddus S, Zawadzki N, Yang D, Damon A, Spurrier K, Batt K, Wei D. Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States. Journal of Medical Economics. 2025 Dec 31;28(1):2082-90.Wang S, Passos Chaves L, Olujohungbe O, Muthukrishnan S, Chaudhary A, Shafrin J. Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures. Journal of Medical Economics. 2025 Dec 31;28(1):2057-70.Chen AJ, Doctor JN, Garrison Jr LP, Goldman DP, Lakdawalla DN, Liden B, Mulligan K, Peneva D, Shafrin J, Phelps CE. Response to the Draft Report of the Health Economics Methods Advisory (HEMA):“Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”. October 20, 2025. https://schaeffer.usc.edu/wp-content/uploads/2025/10/HEMA-responses.Schaeffer-Center.pdfMulvey E, Shafrin J, Than KS, Muthukrishnan S, Mutebi A, Chhibber A, Wang A, Alshreef A, Harb D, Gonzalez V, Quinlan S. Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US. Future Oncology. 2025 Oct 20:1-2.Shafrin J, Zawadzki N, Marin M, Audhya I, Sedita LE, Kulkarni N, Klimchak AC. Caregiver risk preferences for delaying loss of ambulation in Duchenne muscular dystrophy in the United States. Current Medical Research and Opinion. 2025 Aug 3;41(8):1499-509. Shafrin J, Kim J, Fajnor J, Than KS, Mearns ES, Kowal SL, Majda T, Hlávka JP. A Generalized Risk Adjusted Cost Effectiveness (GRACE) Economic Model for Measuring the Value of Interventions that Delay Mobility Impairment Across Neurological Conditions. Value in Health. 2025 Aug 21. Danese MD, Shafrin J, Laurie M, Korytowsky B, Jordan S, Ryan D, Padda SK. Imaging Utilization and Treatment Patterns of Brain Metastases in Patients with Non-Small Cell Lung Cancer: a SEER-Medicare and SEER Database Analysis. Clinical Lung Cancer. 2025 Jul 29. El-Kersh K, Zawadzki N, Watzker A, Zhang S, Dalal D, Lautsch D, Shafrin J. A structured approach for identifying disease analogs for pulmonary arterial hypertension. Journal of Managed Care & Specialty Pharmacy. 2025 Sep;31(9):909-21. Shafrin J, Than KS, Fajnor J, Kim J, Mearns ES, Kowal SL, Majda T, Hlávka JP. Two approaches for measuring treatment value under uncertainty: estimating insurance value and risk preferences in neurology. Forum for Health Economics and Policy 2025 Dec 1 (Vol. 28, No. 1, pp. 21-42). De Gruyter. Shafrin J, Fajnor J, Zhang S, Nichols DE. Factors That Increase Utilization Management Risk: A Proof of Concept. American Journal of Managed Care. 2025 Jun 1;31(6). Kim, Jaehong, Shanshan Wang, Moises Marin, Slaven Sikirica, Mariam Anderson, and Jason Shafrin. “Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease.” Journal of Managed Care & Specialty Pharmacy 31, no. 7 (2025): 641-650. Chung, Andrea P., Jason T. Shafrin, Sachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard C. Alsfeld, Sanjana Muthukrishnan, Anik R. Patel, Gunjan L. Shah, and Richard T. Maziarz. “Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data Analysis.” Blood Advances (2025). Shafrin, Jason, Suhail Thahir, Alexa C. Klimchak, Ivana Audhya, Lauren E. Sedita, and John A. Romley. “Quantifying the altruism value for a rare pediatric disease: Duchenne muscular dystrophy.” The American Journal of Managed Care 31, no. 5 (2025): 240-244. Shafrin, Jason, Shanshan Wang, Khounish Sharma, Kathryn Spurrier, and Robert J. Nordyke. “Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?” Value in Health 28, no. 1 (2025): 25-30. Anyaduba, Uchechukwu Love, Oluwatosin Qawiyy Orababa, Zion Faye, Nazia Rashid, Jason Shafrin, and Gregory Reardon. “Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials.” Cancer Reports 8, no. 5 (2025): e70195.Shafrin, Jason, Shanshan Wang, Jaehong Kim, and Slaven Sikirica. “Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective.” Journal of Managed Care & Specialty Pharmacy 31, no. 4 (2025): 386-395. Tunis, Sean R., Jason Shafrin, Kyi-Sin Than, Melanie D. Whittington, Richard J. Willke, and Murtuza Bharmal. “Use of real-world evidence in the Medicare Drug Price Negotiation Program: A checklist for the Centers for Medicare and Medicaid Services and manufacturers.” Health Affairs Scholar 3, no. 3 (2025): qxaf030. Clayton, Denise, Jason Shafrin, Glorian P. Yen, Lincy Geevarghese, Yulin Shi, and Anem Waheed. “A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria.” Advances in Therapy 42, no. 1 (2025): 500-509.
I was fortunate to work with some amazing co-authors to get all this work done in just one year. I am excited to conduct more interesting research in 2026!
